Like so many other pharmaceutical stocks, Novartis (NYSE:NVS) has done pretty well for its shareholders over the past year and solidly beat the S&P 500. With that move, the multi-year discount in most Big Pharma shares has evaporated and Novartis is no exception. Novartis has a deep and high-potential pipeline, but threats from generic competition, competition to its branded drugs, margin pressure, and strategic uncertainties do mitigate some of that pipeline value.
To read more, please follow this link:
http://www.investopedia.com/stock-analysis/061213/after-good-run-novartis-looks-fairly-valued-nvs-rhhby-bmy-mrk-biib.aspx
Investopedia: After A Good Run, Novartis Looks Fairly Valued
0 comments:
Post a Comment
Click to see the code!
To insert emoticon you must added at least one space before the code.